ERRATUM

Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling

Luca Gelsomino¹ · Guowei Gu² · Yassine Rechoum² · Amanda R. Beyer² ·
Sasha M. Pejerrey² · Anna Tsimelzon² · Tao Wang² · Kenneth Huffman³ ·
Andrew Ludlow³ · Sebastiano Andò¹ · Suzanne A. W. Fuqua^{2,4}

Published online: 24 April 2017
© Springer Science+Business Media New York 2017

Erratum to: Breast Cancer Res Treat (2016)
157:253–265
DOI 10.1007/s10549-016-3829-5

In the original publication of the article, the panel for estrogen receptor (ER) in Fig. 2c was incorrectly published. The corrected Fig. 2 is given in this erratum.

The online version of the original article can be found under
doi:[10.1007/s10549-016-3829-5](https://doi.org/10.1007/s10549-016-3829-5).

✉ Suzanne A. W. Fuqua
sfuqua@bcm.edu

¹ Department of Pharmacy, Health, and Nutritional Sciences,
University of Calabria, Arcavacata di Rende, Cosenza, Italy

² Lester & Sue Smith Breast Center, Baylor College of
Medicine, One Baylor Plaza, Houston, TX 77030, USA

³ Department of Pharmacology, University of Texas
Southwestern Medical Center, Dallas, TX, USA

⁴ Dan L Duncan Cancer Center, Houston, TX, USA

Fig. 2 IGF-1 signaling pathway activation in HBD-ESR1 mutants. **a** Ingenuity pathway analysis (IPA) to identify activation of signaling pathways in mutant MCF-7 versus ZR-75B. **b** Total cellular extracts were analyzed for phosphorylation and expression of ER, IGF1Rβ, IRS-1, and mTOR; GAPDH was used as a loading control.

Immunoblots show a representative example of three experiments. **c** Total cellular extracts were analyzed for phosphorylation and expression of ERα, IGF1Rβ, IRS-1, and mTOR; GAPDH was used as a loading control. Immunoblots show a representative example of three different experiments